Drug intelligence / Profile preview

3-Allylfentanyl

Development stage
Unknown
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Intravenous, Intranasal, Inhalation, Oral
01

Overview

3-Allylfentanyl is a synthetic opioid analgesic and a structural analogue of fentanyl. It acts as an agonist at opioid receptors, primarily the mu-opioid receptor, producing effects similar to fentanyl but with significantly lower potency—approximately 0.13 to 0.14 times as potent by weight compared to fentanyl (ED50 in rats of 80 μg/kg versus 11 μg/kg for fentanyl)[1][2]. The addition of an allyl group reduces its potency relative to the parent compound. Like other opioids in this class, it can cause side effects such as itching, nausea, and potentially life-threatening respiratory depression[1][2]. There is no evidence that it has been developed or marketed for medical use; it is considered a non-pharmaceutical fentanyl derivative.

Other names
3-allyl fentanyl
02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on 3-Allylfentanyl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-Allylfentanyl.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call